Recently, with longer follow-up in KRAS G12C-mutant NSCLC (n = 65), divarasib achieved an ORR of 55.6%, a median duration of response of 18 months, and median PFS of 13.8 months [91]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.